OREX | Fox Lake Towing and Recovery

Tag: OREX

FDA Rejects Orexigen’s New Diet Drug Over Heart Concerns

by Melly Alazraki on Feb.01, 2011, under Towing

FDA Rejects Orexigen's New Diet Drug Contrave Over Heart Concerns

In a surprise move Tuesday, the FDA rejected Orexigen’s proposed new diet drug Contrave, saying the company needed to run another study of its cardiovascular risks. With this rejection, all three of a slate of similar diet drugs from competing pharmaceuticals have been turned back by the agency.

Continue reading FDA Rejects Orexigen’s New Diet Drug Over Heart Concerns

FDA Rejects Orexigen’s New Diet Drug Over Heart Concerns originally appeared on DailyFinance on Tue, 01 Feb 2011 11:17:00.

Filed Under: Company News, Health Care, Stocks in the News

Leave a Comment :@aoloriginal, ABT, Arena, ARNA, Company News, contrave, diet, diet drugs, diet pills, fda, FDA advisory panel, FDA approval, food and drug administration, Health Care, lorecaserin, OREX, OREX, VVUS, ARNA, ABT, Orexigen, phen-fen, Qnexa, Stocks in the News, study, Vivus, VVUS more...

The Top 10 Health Care Stories of 2010

by Melly Alazraki on Dec.29, 2010, under Towing

The health-care reform bill, drug and food recalls, medical breakthroughs, layoffs and lawsuits helped make 2010 an exciting year for health care.

Led by the health insurance reform law, a flurry of drug and food recalls, key medical breakthroughs and plenty of layoffs and lawsuits, 2010 proved to be an exciting — if not always positive — year. Here’s our rundown of the biggest health care stories.

Continue reading The Top 10 Health Care Stories of 2010

The Top 10 Health Care Stories of 2010 originally appeared on DailyFinance on Wed, 29 Dec 2010 07:30:00.

Filed Under: Health Care, Genzyme Corporation , Johnson & Johnson, Pfizer, Sanofi Aventis, Merck, GlaxoSmithKline, Novartis, Abbott, Astrazeneca

Leave a Comment :@aoloriginal, Abbott, ABT, ACL, ACTC, affordable care act, AGN, aids, aids prevention, aids research, aids treatments, ARNA, AstraZeneca, AZN, benadryl recall 2010, biotech, biotech layoffs, cheese recall, childrens medicine, childrens medicine recall, diet drugs, egg recall, egg recall 2010, employer benefits, employer healthcare, fda, FDA Food Safety Modernization Act, fda warning, food safety, food safety bill, GENZ, Genzyme Corporation, GERN, GILD, glaxosmithkline, GSK, health benefits, Health Care, health care reform, health insurance, health insurance costs, Health insurance premiums, health insurance reform, HIV AIDS, hiv prevention, HIV treatment, j j, JNJ, JNJ, GILD, OREX, ARNA, VVUS, AZN, PFE, MRK, NVS, ACL, SNY, GENZ, AGN, ABT, GSK, GERN, ACTC, RHHBY, Johnson & Johnson, johnson and johnson, Medicaid, Merck, motrin recall, MRK, Mylanta, Novartis, NVS, obesity, OREX, pfe, Pfizer, pharma, pharma layoffs, pharmaceutical industry, RHHBY, rolaids recall 2010, sanofi-aventis, SNY, VVUS, weight loss more...

FDA Panel Backs Orexigen’s Diet Pill

by Melly Alazraki on Dec.07, 2010, under Towing

An FDA panel of reviewers has voted to recommend approval of Orexigen's weight-loss drug Contrave.

After the U.S. Food and Drug Administration rejected two other weight-loss pills earlier this year, an advisory panel has recommended the approval of Orexigen Therapeutics’s Contrave. If the FDA follows the recommendation, Contrave could become the first diet drug to win approval in a decade.

Continue reading FDA Panel Backs Orexigen’s Diet Pill

FDA Panel Backs Orexigen’s Diet Pill originally appeared on DailyFinance on Tue, 07 Dec 2010 20:30:00.

Filed Under: Company News, Health Care, Stocks in the News

1 Comment :@aoloriginal, AGN, Arena, ARNA, Company News, contrave, diet pill, diet pills, dieting, drugs, fda, fda approva, food and drug administration, Health Care, OREX, OREX, ARNA, VVUS, AGN, Orexigen, pharma, pharmaceutical, Qnexa, Stocks in the News, VVUS, weight loss, weight loss drugs more...

Vivus Shares Rally on Hopes Obesity Drug Will Gain Approval Next Year

by Melly Alazraki on Oct.29, 2010, under Towing

Vivus shares are soaring this morning, even though the U.S. Food and Drug Administration rejected the drugmaker’s obesity drug Qnexa yesterday. Investors are hoping that the FDA’s rejection, which includes a request for more safety data — not another clinical trial — will lead to approval next year.

Continue reading Vivus Shares Rally on Hopes Obesity Drug Will Gain Approval Next Year

Vivus Shares Rally on Hopes Obesity Drug Will Gain Approval Next Year originally appeared on DailyFinance on Fri, 29 Oct 2010 11:10:00.

Filed Under: Company News, Health Care, Stocks in the News

Leave a Comment :ABT, ARNA, Company News, diet drugs, diet pills, drug approval, fda, Health Care, obesity, obesity in America, obesity medication, obesity pills, obesity treatment, OREX, Orexigen, pharmaceutical companies, pharmaceutical stocks, Stocks in the News, Vivus, VVUS, VVUS, ABT, ARNA, OREX more...

Arena Shares Finish Higher After FDA Rejects Obesity Drug Lorcaserin

by Melly Alazraki on Oct.25, 2010, under Towing

Arena Pharmaceuticals announced, as expected, the U.S. Food and Drug Administration did not approve its weight loss drug Lorcaserin for patients who are obese and overweight because the potential risks outweigh the minimal efficacy.

Continue reading Arena Shares Finish Higher After FDA Rejects Obesity Drug Lorcaserin

Arena Shares Finish Higher After FDA Rejects Obesity Drug Lorcaserin originally appeared on DailyFinance on Mon, 25 Oct 2010 16:00:00.

Filed Under: Company News, Abbott